Quadalti, Corinne
Palmqvist, Sebastian http://orcid.org/0000-0002-9267-1930
Hall, Sara
Rossi, Marcello
Mammana, Angela
Janelidze, Shorena http://orcid.org/0000-0003-2869-8378
Dellavalle, Sofia
Mattsson-Carlgren, Niklas
Baiardi, Simone http://orcid.org/0000-0002-7702-7856
Stomrud, Erik
Hansson, Oskar http://orcid.org/0000-0001-8467-7286
Parchi, Piero http://orcid.org/0000-0002-9444-9524
Article History
Received: 21 January 2023
Accepted: 8 June 2023
First Online: 18 July 2023
Competing interests
: None of the authors has any financial interest in the α-syn SAA test. S.P. has acquired research support (for the institution) from ki elements/Alzheimer Drug Discoveries Foundation. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Lilly and Roche. O.H. has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. M.R., S.H., C.Q., N.M.C., S.D., A.M., S.J., S.B., E.S. and P.P. declare no competing interests.